CLAIMS

1. A compound of the formula:



in which:

a. M is NZ or O;

b. Z is represented by H or C_1- C_4 alkyl;

c. R^1 is represented by hydrogen, (C_1-C_2)alkyl, optionally substituted with one or more halogens, or (C_1-C_2)alkoxy, optionally substituted with 1 or more halogens;

d. R^2 is absent, or may represent up to 2 substituents selected from the group consisting of halogen, nitrile, hydroxy, (C_1-C_4)alkyl, (C_2-C_4)alkenyl, (C_2-C_4)alkynyl, (C_1-C_4)alkoxy, (C_1-C_2)alkyl substituted with 1 or more halogens, (C_1-C_2)alkoxy substituted with one or more halogens, SR^4, and NR^4R^5;

e. A is represented by $-S(O_2)$;

f. B completes a heterocyclic ring;

g. R^3 may be absent, or may represent up to 2 substituents selected from the group consisting halogen, hydroxy, nitrile, (C_1-C_4)alkoxy, (C_1-C_4)alkyl, optionally substituted heterocyclic , optionally substituted heteroaryl, optionally substituted phenyl, -$[CH_2]_mC(O)OR^4$, -$[CH_2]_mC(O)R^4$, -$[CH_2]_mC(O)NR^4R^5$, (C_1-C_4)alkylR^6, -$[CH_2]_n$-Y-$[CH_2]_m$-X-$[CH_3]_q$, (C_3-C_8)cycloalkyl, and -SR^4 -

h. R^4 is represented by hydrogen, (C_1-C_4)alkyl, optionally substituted benzyl, optionally substituted phenyl, optionally substituted

heteroaryl, or optionally substituted heterocyclic or R^4 and R^5 together with the adjacent nitrogen atom can combine to form a heterocyclic or heteroaryl ring;

i. R^5 is represented by hydrogen, optionally substituted phenyl, (C_1-C_4)alkyl, or optionally substituted benzyl;

j. R^6 is represented by optionally substituted phenyl, optionally substituted heteroaryl, or optionally substituted heterocyclic;

k. n is an integer selected from 1, 2, 3, or 4;

l. Y is absent, or is represented by O, C(O),OH, SH, or S;

m. m is represented by an integer selected from 0, 1, 2, 3, or 4;

n. X is absent, or is represented by O, C(O),OH, SH or S; and

o. q is represented by the integer 0 or 1, and; the pharmaceutically acceptable salts, solvates, and prodrugs thereof with the prevision that if both X and Y are present, then M is not zero.

2. The compound of claim 1 in which R^1 is represented by trifluoromethyl.

3. The compound of claim 2 in which M is NZ, in which Z is hydrogen.

4. The compound according to claim 2 in which B complete a 5 or 6 member sulfur containing heterocylic ring.

5. The compound according to claim 3 in which B complete a 5 or 6 member sulfur containing heterocylic ring.

6. The compound according to claim 2 in which B complete a 5 or 6 member nitrogen containing heterocylic ring

7. The compound according to claim 2 in which B complete a 5 or 6 member nitrogen containing heterocylic ring

8. The compound according to claim 2 in which B complete a 5 or 6 member oxygen containing heterocylic ring

9. The compound according to claim 2 in which B complete a 5 or 6 member oxygen containing heterocylic ring

10. The compound according to claim 2 in which B is selected from the group consisting of azocane, piperidine, piperazine, pyrrolidine, isoquinoline, thiazolidine, morpholine, azepane, and azetidine.

11. The compound according to claim 3 in which B is selected from the group consisting of azocane, piperidine, piperazine, pyrrolidine, isoquinoline, thiazolidine, morpholine, azepane, and azetidine.

12. The compound according to claim 1 in which said compound is selected from the group consisting of:

6-(Azocane-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(4-Pyrrolidin-1-ylpiperidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-[4-(4-Methoxyphenyl)-3-methylpiperazine-1-sulfonyl]-4-trifluoromethyl-1H-quinolin-2-one;

1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinoline-6-sulfonyl)piperidine-4-carboxylic acid ethyl ester;

6-(4-Hydroxy-4-thiophen-2-ylpiperidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(4-Furan-2-ylmethylpiperazine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(1,3-Dihydroisoindole-2-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinoline-6-sulfonyl)pyrrolidine-2-carboxylic acid methyl ester;

6-{4-[2-(2-Hydroxyethoxy)-ethyl]piperazine-1-sulfonyl}-4-trifluoromethyl-1H-quinolin-2-one;

6-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinoline-2-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(1,4-Dioxa-8-azaspiro[4.5]decane-8-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-[4-(2-Oxo-2-pyrrolidin-1-ylethyl)piperazine-1-sulfonyl]-4-trifluoromethyl-1H-quinolin-2-one;

6-(4-Methylpiperidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(3-Hydroxymethylpiperidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(Thiazolidine-3-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(4-Pyridin-4-ylpiperazine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(4-Phenylpiperazine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-[2-(2-Hydroxyethyl)-piperidine-1-sulfonyl]-4-trifluoromethyl-1H-quinolin-2-one;

6-(2-Hydroxymethyl-pyrrolidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(Octahydroquinoline-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-[4-(2-Thiophen-2-ylethyl)piperazine-1-sulfonyl]-4-trifluoromethyl-1H-quinolin-2-one;

6-(Pyrrolidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(2,6-Dimethylmorpholine-4-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(2-Oxa-5-azabicyclo-[2.2.1]heptane-5-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(Azepane-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(2-Methylpiperidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(4-Cyclopentylpiperazine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(Azetidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(4-Pyridin-2-ylpiperazine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(2,3,5,6-Tetrahydro-[1,2']bipyrazinyl-4-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

1-(1-Methyl-2-oxo-4-trifluoromethyl-1,2-dihydroquinoline-6-sulfonyl)piperidine-4-carboxylic acid ethyl ester;

6-(1,3-Dihydroisoindole-2-sulfonyl)-1-methyl-4-trifluoromethyl-1H-quinolin-2-one;

6-(4-Ethylpiperazine-1-sulfonyl)-1-methyl-4-trifluoromethyl-1H-quinolin-2-one;

6-{4-[2-(2-Hydroxyethoxy)-ethyl]piperazine-1-sulfonyl}-1-methyl-4-trifluoromethyl-1H-quinolin-2-one;

1-Methyl-6-(thiazolidine-3-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

1-Methyl-6-(octahydro-quinoline-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one;

6-(Azepane-1-sulfonyl)-1-methyl-4-trifluoromethyl-1H-quinolin-2-one;

6-(2,6-Dimethylmorpholine-4-sulfonyl)-1-methyl-4-trifluoromethyl-1H-quinolin-2-one; and

6-(3,4-Dihydro-2H-quinoline-1-sulfonyl)-1-methyl-4-trifluoromethyl-1H-quinolin-2-one.

13. The compound according to Claim 1 in which said compound is selected from the group consisting of 6-(thiazolidine-3-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one, 6-(azocane-1-sulfonyl)-4-trifluoromethyl-1H-quinolin-2-one, and 6-[4-(piperidine-1-sulfonyl)]-4-trifluoromethyl-1H-quinolin-2-one.

14. A method for inhibiting activation of the androgen receptor comprising administering an effective amount of a compound according to claim 1 to a patient in need thereof.

15. A method for the alleviating a condition selected from the group consisting of alopecia, acne, oily skin, prostrate cancer, hirsutism, and benign prostate hyperplasia, comprising administering a compound according to claim 1 to a patient in need thereof.

16. A pharmaceutical composition comprising a compound according to claim 1 in admixture with 1, or more, pharmaceutically acceptable excipients.

17. A topical pharmaceutical formulation comprising a compound according to claim 1 in admixture with 1, or more, pharmaceutically acceptable excipients suitable for dermal application.

18. An article of manufacture comprising a compound according to claim 1 packaged for retail distribution, which advises a consumer how to utilize

the compound to alleviate a condition selected from the group consisting of acne, alopecia, and oily skin.